GYRE — Gyre Therapeutics Cashflow Statement
0.000.00%
- $1.30bn
- $1.29bn
- $113.45m
Annual cashflow statement for Gyre Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -55.2 | -56.2 | -87.9 | -8.24 | -85.5 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 3.2 | 3.63 | 3.4 | -20.1 | 105 |
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 8.21 | -2.57 | 0.483 | -4.95 | 6.83 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | -43.6 | -55 | -83.8 | -33.1 | 25.9 |
Capital Expenditures | -0.064 | -0.267 | -0.839 | 0 | -8.59 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 27.5 | 9.93 | 49 | 55.4 | -11.2 |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 27.4 | 9.66 | 48.2 | 55.4 | -19.8 |
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 0.327 | 60.4 | 49.6 | -45 | 2.5 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -15.9 | 15 | 14 | -22.7 | 8.33 |